Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Sergey V. Kozin, Mari Mino et al.|Nature Medicine|2004Cited by 2k
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al.|Journal of Clinical Oncology|2009Cited by 507
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419
Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic CancerYves Boucher, Rakesh K. Jain|Clinical Cancer Research|2023Cited by 47
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patientsYves Boucher, Rakesh K. Jain|npj Precision Oncology|2021Cited by 41